Genentech, Inc.

Nurix Therapeutics, Inc.

Achaogen, Inc.

Gilead Sciences, Inc.

Array Biopharma Inc.

Inotek Pharmaceuticals Corporation

F. Hoffmann-la Roche Ag

Curis, Inc.

Frederick Cohen

John A Flygare

Vickie Hsiao-Wei Tsui

Lewis J Gazzard

Hunter Paul Shunatona

Christoph Wolfgang Zapf

Mario G Cardozo

Arthur T Sands

Jennifa Gosling

Dahlia Weiss

Thomas Cummins

Neil F Bence

Hiroko Tanaka

Chenbo Wang

Wayne J Fairbrother

Cuong Q Ly

Kurt Deshayes

Bainian Feng

Martin Sheringham Linsell

James Bradley Aggen

Snahel Patel

Paola Dozzo

Micah James Gliedt

Qing Lu

Darin James Hildebrandt

Michael F T Koehler

Timothy Robert Kane

Glenn McEnroe

Brian D Patterson

Ramesh Annasaheb Kasar

Xianrui Zhao

Joseph P Lyssikatos

James F Blake

Daniel P Sutherlin

Anthony A Estrada

Steven Armen Boyd

John Joseph Gaudino

Xiaojing Wang

Prakash Jagtap

Zhonghua Pei

Daniel Fred Ortwine

Jeongbeob Seo

Chudi Obioma Ndubaku

Wendy B Young

Allison L Marlow

Michael Siu

Lan Wang

Kin Chiu Fong

John Buell

Allen A Thomas

Philippe Bergeron

Malcolm Huestis

Hongqi Tian

Jason De Meese

Kevin Hon Luen Lau

Duy-Phong Pham-Huu

Beni B Wolf

Tomas Kaplan

Clifford Quan

Stephen Franz Keteltas

Ryan Pemberton

Mark Edward Zak

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof

The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.

Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof

Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R, R, R, R, Rand Rare as described herein.

Inhibitors of IAP

3-substituted piperidine compounds for Cbl-b inhibition, and use thereof

Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof

The present invention provides for pyrimidine compounds of Formula I-I and embodiments thereof  In Formula I-I in which R, R, R, R, R, R, m, n and the 'het' ring are as described herein. Also provided are pharmaceutical compositions comprising compounds of Formula I and methods of using such compounds and compositions.

C-linked heterocycloaklyl substituted pyrimidines and their uses

Antibacterial compounds of formula (I) are provided: as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.

Antibacterial agents

The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof.  In compounds of Formula I, the groups R, R, R, R, R, R, m, n and the C-linked Ring have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula I as DLK inhibitors and for treating neurodegeneration diseases and disorders.

Substituted dipyridylamines and uses thereof

Growing community of inventors

San Francisco, CA, United States of America

Frederick Cohen